Since their inception in the mid-1960s, liposomes have become an important, if not the critical, nanoparticle in the pharmaceutical industry, with applications ranging from magnetic resonance imaging to biosensors to drug delivery1. In the area of drug delivery there are presently over 30 liposome formulations involved in clinical trials at the U.S. Food and Drug Administration, targeting breast, prostate and ovarian cancer, among others.

This content is only available as a PDF.